Remedium Capital Partners, LLC
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 19, 2026), Remedium Capital Partners, LLC reported 6 stock positions worth $281.2 million. Its top holding was Oruka Therapeutics (ORKA) at 27.3% of the portfolio, followed by Spyre Therapeutics (SYRE, 26.1%) and Damora Therapeutics (DMRA, 18.8%). Compared with Q4 2025, it added to 2. The biggest buy was Damora Therapeutics (DMRA, shares +1598%).
- Most Recent 13F
- Q2 2026
- Location
- WEST PALM BEACH, FL
- CIK
- 0002104501
- Portfolio Value
- $281.2M (Q1 2026)
- SEC Filing
- 0002104501-26-000010 ↗ filed May 19, 2026
Holdings Value
Holdings 6 stocks · $281.2M
| ORKA Oruka Therapeutics Inc. | 27.31% | 1,565,661 | $76.8M | Add +0.8% |
| SYRE Spyre Therapeutics Inc. | 26.13% | 1,456,231 | $73.5M | No change |
| DMRA Damora Therapeutics Inc. | 18.84% | 2,045,473 | $53.0M | Add +1597.9% |
| APGE Apogee Therapeutics Inc. | 17.47% | 583,591 | $49.1M | No change |
| JBIO Jade Biosciences Inc. | 7.88% | 1,577,750 | $22.2M | No change |
| CBIO Crescent Biopharma Inc. | 2.36% | 361,250 | $6.6M | No change |
Portfolio Sells Q4 2025 → Q1 2026
| None this quarter. | |||